SEC Comment Letter 0000000000-24-004529 to RenovoRx, Inc. (RNXT)
RenovoRx, Inc.
Date: April 24, 2024 · CIK: 0001574094 · Accession: 0000000000-24-004529
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278841
Letter
United States securities and exchange commission logo April 24, 2024 Shaun R. Bagai Chief Executive Officer RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 Re:RenovoRx, Inc. Registration Statement on Form S-3 Filed April 19, 2024 File No. 333-278841 Dear Shaun R. Bagai: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Scott M. Miller, Esq.
Show Raw Text
United States securities and exchange commission logo
April 24, 2024
Shaun R. Bagai
Chief Executive Officer
RenovoRx, Inc.
4546 El Camino Real, Suite B1
Los Altos, CA 94022
Re:RenovoRx, Inc.
Registration Statement on Form S-3
Filed April 19, 2024
File No. 333-278841
Dear Shaun R. Bagai:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Scott M. Miller, Esq.